Celmatix, a biotech company based in New York, is on a mission to delay menopause. The company is developing a drug regimen with the goal of delaying the onset of menopause by 10-15 years for reasons beyond extending the fertility window. These reasons include delaying the onset of certain health and vitality issues that increase after menopause, such as osteoporosis, fatigue, and a less healthy cholesterol profile.
CEO Piraye Beim believes it is important to draw a clear distinction between a woman’s endocrine function and reproduction: optimizing endocrine function is not just about increasing a woman’s fertility or prolonging her fertile years. According to Beim, “The ovary isn’t just about babies… If we could buy women an extra 10 to 15 years of natural endocrine function, we’re talking about a huge boost in their vitality and their wellness at a critical stage in their life. It will align us more with men, basically.”
The drug program Celmatix is developing aims to delay the depletion of ovarian follicles. It mimics anti-mullerian hormone, a hormone that helps regulate the ovaries. Beim is optimistic about Celmatix’s future and the future of women’s health therapeutics more broadly, which she would like to have a part in advancing. According to Beim, the field of women’s health therapeutics has been relatively stagnant over the last 100 years, but broader cultural shifts around women’s empowerment have caused pharmaceutical companies to become newly interested in the topic.
Beim wants to be in clinical trials with Celmatix’s drug program by 2023, first testing its drug on women undergoing chemotherapy, which commonly causes premature menopause.